Bishops’ pro-life chair ‘urgently’ encourages FDA to proceed with safety review on mifepristone
The head of the bishops' pro-life committee has written to Trump administration officials his concerns about the status of their mifepristone safety review.
about 11 hours ago
The chair of the U.S. bishops’ pro‑life committee has issued an urgent appeal for the Food and Drug Administration to move forward with its safety review of the abortion medication mifepristone 1.
The pro‑life chair’s statement emphasizes the need for a prompt continuation of the FDA’s evaluation of mifepristone’s safety profile 1.
The FDA is conducting a safety review of mifepristone, a drug commonly used to terminate early pregnancies 1.
A swift FDA decision could affect the availability and regulatory status of mifepristone across the United States 1.
Assess Catholic doctrinal stance on FDA mifepristone review
Catholic doctrine does not treat “reviewing safety” of an abortion drug as the same thing as endorsing abortion. The Church’s stance is twofold: (1) direct abortion is intrinsically immoral and never permitted, and (2) Catholics may urge regulators to protect women’s health (informed consent, transparency, and minimizing harm) while still refusing to call the act morally good.
The Catechism teaches that human life must be protected “from the moment of conception,” and that direct abortion—“abortion willed as an end or a means”—is gravely contrary to the moral law and remains “unchangeable.”
It further states:
A USCCB doctrinal note on technological interventions emphasizes that technology can be used for good, but not without moral limits grounded in the created order and the body-soul unity of the human person.
It states that neither patients nor physicians have unlimited rights over the body; the patient “is the user and not the owner.”
Crucially, it explains that Church moral tradition recognizes essentially two morally permissible scenarios for bodily interventions:
1) repairing a defect, or
2) sacrificing a part for the welfare of the whole—with stringent conditions.
It also notes that other interventions that aim to alter the fundamental order of the body do not respect that order and are not morally justified.
A USCCB doctrinal clarification (in response to confusion after a reported case) draws a decisive distinction:
The document summarizes the relevant Ethical and Religious Directives teaching:
Catholic doctrine evaluates the moral object and intention of the act. If mifepristone is used as part of a regimen whose purpose is the direct termination of pregnancy before viability, that falls under direct abortion as Catholics understand the term in the Church’s teaching.
Therefore, from a doctrinal perspective, the Church cannot regard the use of mifepristone as an abortion as morally legitimate “medicine,” even if it is medically administered and even if a woman experiences real hardship.
The USCCB (through a coalition letter) urged the FDA that, because of concerns about telemedicine chemical abortion, the FDA has an “ethical obligation to protect women from the dangers that mifepristone presents to women’s health and safety.”
In the same letter, Catholic health/pastoral organizations ask for concrete regulatory steps such as:
Doctrinally, this can be coherent with Catholic ethics because the Church strongly affirms obligations to protect bodily health and to avoid wrongdoing. The USCCB’s broader doctrinal note also recognizes that patients have a duty to care for their health and that moral licitness depends in part on appropriate benefit/burden and real risk evaluation.
However, Catholic doctrine still does not follow that “harm reduction” or improved consent automatically means the underlying abortion act becomes morally good. The Church’s moral logic remains: you cannot will an intrinsic evil as a means to a good end.
A likely misunderstanding is to treat any pro-safety posture as moral approval. Catholic teaching separates:
Catholic teaching does allow certain medical actions in pregnancy when the direct purpose is to treat a serious condition of the mother, with the child’s death as an unintended side effect.
But that category is not the same as using mifepristone to bring about the termination of pregnancy as such. The double-effect principle is specifically about preventing a serious maternal pathology, not about intending abortion as the mechanism.
Catholic doctrine holds that direct abortion (including chemical abortion intended to terminate pregnancy before viability) is never permitted, grounded in the sacredness of human life and the prohibition on directly destroying an innocent human being. At the same time, Catholics can legitimately urge the FDA to improve safety, informed consent, transparency, and oversight in order to protect women from harm—without treating the underlying act as morally legitimate.